Open AccessThe Safety and Efficacy of Neoadjuvant Camrelizumab Plus Chemotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Study
Author(s) -
Geping Yin,
Zu-Lei Li,
Dong Liu
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s358620
Subject(s) - medicine , esophageal squamous cell carcinoma , oncology , chemotherapy , neoadjuvant therapy , retrospective cohort study , basal cell , carcinoma , cancer , breast cancer
Neoadjuvant anti-programmed death receptor-1 (PD-1) blockade has been explored in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). We conducted this study to assess the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy in locally advanced ESCC.